Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company ImVisioN Therapeutics AG
DescriptionImmunotherapy combining Modular Antigen Transport (MAT) technology with the Fel d1 cat dander allergen
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationAllergy
Indication DetailsTreat cat dander allergy
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today